search
drug discovery
Trends
- 1Roche outlines plans for autonomous AI laboratories●Roche outlines plans to move towards autonomous AI labs
Roche has outlined plans to move towards autonomous AI laboratories, according to a Reuters report. The Swiss pharmaceutical company intends to use artificial intelligence to run elements of its research operations with reduced human involvement, a step that would put it among the first major drugmakers to pursue fully automated, AI-driven labs.
- 2Basecamp Research raises $140M to map biodiversity with AI▼UK-based Basecamp Research raised $140M to map global biodiversity for drug discovery. By training AI on genetic data fr
UK-based Basecamp Research has raised $140 million to map global biodiversity for drug discovery. The company trains AI on genetic data from unexplored organisms to help design new therapies. Commenters note that scaling the work will depend on proving safety in human trials and ensuring fair benefit-sharing with the countries and communities where genetic material originates.
- 3AI's biggest payoff could be better medicines●The AI boom’s biggest payoff could be better medicines
Commentators argue that the clearest real-world benefit of the current AI boom may come in medicine, where artificial intelligence can speed up drug discovery, identify promising compounds, and shorten the path from lab research to approved treatments. The claim suggests that beyond consumer chatbots and productivity tools, healthcare and pharmaceuticals could be where AI delivers its most valuable results for society.
- 4OpenAI leads $150M funding round for drug revival startup Biossil▼OpenAI leads $150M round for drug-reviving startup Biossil
OpenAI has led a $150 million investment round in Biossil, a startup focused on reviving abandoned drugs. The company specializes in taking discontinued or shelved pharmaceutical compounds and finding new paths to develop them. It is a notable move for OpenAI's investment arm, signaling growing interest in applying AI to drug discovery and development, and fresh attention on the drug-repurposing sector.